Transgene S.A

Transgene is a biotechnology company based in Illkirch-Graffenstaden (67400) which designs and develops innovative clinical and pre-clinical immunotherapies.
Transgene's portfolio consists of four immunotherapies in clinical development: two therapeutic vaccines (TG4001 and TG4050) and three oncolytic viruses using the Invir.I® virus (TG6002, BT-001 and TG6050).
With myvac®, therapeutic vaccination enters precision medicine with innovative immunotherapy specific to each patient. This immunotherapy makes it possible to integrate, in a viral vector, tumor mutations identified and selected thanks to artificial intelligence provided by its partner NEC.
Invir.I®, a platform resulting from Transgene's expertise in viral vector engineering, makes it possible to design a new generation of multifunctional oncolytic viruses. Transgene has signed a collaboration agreement with AstraZeneca relating to this platform.